Featured-Rx

Colorado and Michigan have joined Oklahoma to become the nation’s pioneering states with approved State Plan Amendments (SPAs) that enable Medicaid alternative payment models (APMs) for prescription drugs in the form of outcome-based contracts with pharmaceutical manufacturers. In early May, state experts from Oklahoma, Colorado, and Michigan shared their experiences implementing their APMs during a […]

Read More
  • State Health Policy Blog

    New Law Enables New Mexico to Leverage State Purchasing Power to Lower Rx Spending

    New Mexico Gov. Lujan Grisham recently signed into law SB 131, establishing a state Interagency Pharmacy Purchasing Council to leverage public purchasing power by reviewing and coordinating cost-containment strategies through procurement of pharmaceuticals, pharmaceutical benefits, and pooling of risk among state agencies. Cosponsored by state Sen. Jeff Steinborn* and Rep. Joanne Farrary, the law also […]

    Read More
  • Publications

    State Initiatives Using Purchasing Power to Achieve Drug Cost Containment

    This report focuses on several state purchasing strategies designed to achieve concessions in negotiations with drug manufacturers and in other parts of the prescription drug supply chain. The highlighted strategies include intrastate actions, which combine state agencies’ purchases of drugs to improve their negotiating clout, and interstate activities, such as multi-state organizations that unite to […]

    Read More
    April 15, 2019 | Filed under: Featured-Rx, Front Page-Rx, Medicaid, Payment Reform, Publications

  • Publications

    Cross-Agency Strategies to Curb Health Care Costs: Leveraging State Purchasing Power

    Rising health care costs are an intractable problem in the United States, but states, faced with balanced budget requirements and growing voter concern, aren’t waiting for a federal solution. This report explores state initiatives to curb health care costs by:  Leveraging Medicare’s well-established reimbursement rates as reference prices for state employee plans to address rising […]

    Read More
  • State Health Policy Blog

    State Laws Help Spur Congressional Action on Drug Prices

    Unrelenting and unpredictable increases in prescription drug prices have spurred states to try to unlock the black box of manufacturer pricing strategies by requiring disclosure of how prices are set and how rebates are handled throughout the supply chain. Six states already have transparency laws on their books and almost two dozen more have introduced […]

    Read More
  • Maps
    State Legislative Action to Lower Pharmaceutical Costs

    State Legislative Action to Lower Pharmaceutical Costs

    Updated June 5, 2019* Find the status of state legislation to address prescription drug costs below. Use the category button to search by type of legislation and roll over a state to view its pending drug legislation. Download or view a chart listing 2019 legislation by state. View state action in 2018, 2017, and 2015-2016. Email information about new bills or legislative action to Sarah Lanford. This map […]

    Read More
    January 7, 2019 | Filed under: Featured, Featured-Rx, Front Page-Rx, Maps, Rx Featured New

  • State Health Policy Blog
    Oklahoma Signs the Nation’s First State Medicaid Value-Based Contracts for Rx Drugs

    Oklahoma Signs the Nation’s First State Medicaid Value-Based Contracts for Rx Drugs

    On the heels of Oklahoma’s first-in-the-nation, value-based purchasing deal to improve adherence to an antipsychotic drug, the state’s Medicaid agency just signed its second value-based contract for a prescription drug used to treat serious bacterial skin infections. While several private insurers have initiated value-based contracting, which links payments to a drug’s effectiveness and outcome, Oklahoma […]

    Read More
  • NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database

    NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database

    NASHP’s Center for State Rx Drug Pricing seeks a partner to provide technical and strategic expertise to help a workgroup of state officials from California, Nevada, Oregon, Connecticut, and Vermont implement their drug cost transparency laws and help Maine and New Hampshire develop transparency programs as mandated by recent legislation. This work will help all […]

    Read More
    September 18, 2018 | Filed under: Drug Pricing, Featured-Rx, Front Page, Front Page-Rx, Transparency

  • State Health Policy Blog
    As States Take the Lead to Address Drug Costs, Federal Action Follows

    As States Take the Lead to Address Drug Costs, Federal Action Follows

    *Update: On Oct. 10, 2018, President Trump signed two bills designed to increase prescription drug price transparency by prohibiting gag clauses, which prevent pharmacists from disclosing lower-cost drug options to consumers. One bill prohibits gag clauses under Medicare Part D starting in 2020 and the other affects private insurance markets and goes into effect immediately. […]

    Read More
  • State Health Policy Blog
    New NASHP Model Legislation Helps States Bring Transparency to Pharmacy Benefit Managers

    New NASHP Model Legislation Helps States Bring Transparency to Pharmacy Benefit Managers

    The National Academy for State Health Policy (NASHP) has released model legislation to help states shed light on the opaque business practices of pharmacy benefit managers (PBMs). States can use the model bill to require the licensing of PBMs, ban gag clauses that prevent pharmacists from sharing lower-price drug options with consumers, and require more […]

    Read More